Jaguar Animal Health to Participate in 29th Annual ROTH Conference the Week of March 13th in Orange County, California
March 03 2017 - 9:00AM
Business Wire
Management will be available to schedule
meetings during the conference
Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar”), an animal
health company focused on developing and commercializing
first-in-class gastrointestinal products for companion and
production animals, foals, and high value horses, announced today
that it has been invited to present at the 29th Annual ROTH
Conference to be held at The Ritz-Carlton, Laguna Niguel in Dana
Point, California from Sunday, March 12th through Wednesday, March
15th.
Jaguar’s president and CEO, Lisa Conte, is currently scheduled
to present at the conference on Wednesday, March 15th from
7:30-8:00 AM pacific time. She will also be available for
one-on-one meetings with new and existing analysts, investors and
partners at the conference. Those interested in scheduling a
one-on-one meeting with Ms. Conte are advised to visit the
conference website (click here).
About Jaguar Animal Health, Inc.
Jaguar Animal Health, Inc. is an animal health company focused
on developing and commercializing first-in-class gastrointestinal
products for companion and production animals, foals, and high
value horses. Canalevia™ is Jaguar’s lead prescription drug product
candidate, intended for the treatment of various forms of diarrhea
in dogs. Equilevia™ (formerly referred to as SB-300) is Jaguar’s
prescription drug product candidate for the treatment of
gastrointestinal ulcers in horses. Canalevia™ and Equilevia™
contain ingredients isolated and purified from the Croton lechleri
tree, which is sustainably harvested. Neonorm™ Calf and Neonorm™
Foal are the Company’s lead non-prescription products. Neonorm™ is
a standardized botanical extract derived from the Croton lechleri
tree. Canalevia™ and Neonorm™ are distinct products that act at the
same last step in a physiological pathway generally present in
mammals. Jaguar has nine active investigational new animal drug
applications, or INADs, filed with the FDA and intends to develop
species-specific formulations of Neonorm™ in six additional target
species, formulations of Equilevia™ in horses, and Canalevia™ for
cats and dogs.
For more information, please visit
www.jaguaranimalhealth.com.
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements” within the meaning of section 27A of
the Securities Act of 1933 and section 21E of the Securities
Exchange Act of 1934. These include statements regarding Jaguar’s
intention to develop species-specific formulations of Neonorm™ in
six additional target species, formulations of Equilevia™ in
horses, and Canalevia™ for cats and dogs. In some cases, you can
identify forward-looking statements by terms such as “may,” “will,”
“should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “potential” or “continue” or the negative of these terms
or other similar expressions. The forward-looking statements in
this release are only predictions. Jaguar has based these
forward-looking statements largely on its current expectations and
projections about future events. These forward-looking statements
speak only as of the date of this release and are subject to a
number of risks, uncertainties and assumptions, some of which
cannot be predicted or quantified and some of which are beyond
Jaguar’s control. Except as required by applicable law, Jaguar does
not plan to publicly update or revise any forward-looking
statements contained herein, whether as a result of any new
information, future events, changed circumstances or otherwise.
Jaguar-JAGX
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170303005358/en/
KCSA Strategic CommunicationsGarth Russell,
212-896-1250grussell@kcsa.com
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Jul 2023 to Jul 2024